Product Development Sample Clauses
The PRODUCT DEVELOPMENT clause outlines the responsibilities and procedures related to the creation, design, and improvement of products under an agreement. It typically specifies which party is responsible for developing the product, the standards or specifications to be met, and any timelines or milestones for completion. For example, it may require one party to deliver prototypes or updates at certain stages, or to collaborate on technical requirements. The core function of this clause is to ensure that both parties have a clear understanding of their roles and expectations in the product development process, thereby reducing misunderstandings and facilitating successful project outcomes.
POPULAR SAMPLE Copied 17 times
Product Development. (a) Supplier may develop enhancements it intends to incorporate into the BioGlue Surgical Adhesive during the term of this Agreement that have potential application to the Company Product (“Enhancements”). Unless otherwise agreed by the parties, at least once every six months during the Term, representatives of each of BioForm and Supplier shall hold a meeting in accordance with Sections 4.4 and 8.4 (the “Product Development Meeting”) at which Supplier will present Enhancements for BioForm to consider for application to the Company Product. At such Product Development Meeting, BioForm will also present its marketing plans (pursuant to Section 4.4) for the period and any information or feedback that BioForm reasonably believes may lead to Improvements. Within 30 calendar days following each Product Development Meeting, Supplier shall deliver a notice to BioForm (the “Enhancements Notice”) that shall describe the Enhancements that were presented by Supplier at such Product Development Meeting. Within 30 calendar days following receipt of the Enhancements Notice, BioForm may notify Supplier in writing if BioForm elects that any Enhancement described in the Enhancements Notice shall become an Improvement. If BioForm does provide such notice to Supplier during such 30-calendar day period, then BioForm and Supplier shall agree on a timeline for implementation of the Improvement in new Product Specifications for Company Product. If BioForm does not provide such a notice, said Enhancement shall not be implemented into the Company Product. The Enhancements Notice may also describe any potential Enhancements presented by Supplier at the Product Development Meeting, but BioForm shall not be required to take any action under this Section 8.4 with respect to such potential Enhancements until such time as they are presented by Supplier as Enhancements at a future Product Development Meeting. All Enhancements and potential Enhancement information provided by Supplier shall be considered Supplier Confidential Information.
(b) From time to time, each party may request the other party to participate in joint projects to develop Improvements. Neither party is obligated to participate in such projects, and in each **** Certain information on this page has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. instance, each party’s decision whether to participate will be ma...
Product Development. Work with tourism partners to undertake research, surveys and data analysis. Collaborate with tourism partners to undertake product or asset inventories; develop itineraries; improve the market-readiness of existing tourism experiences; undertake market-match studies; showcase local distinctiveness; create/develop new niche tourism products to entice and target new visitors (e.g., gardens, culinary, golf, biking, etc.); create tour routes; implement signage; and/or enhance programming and interpretation of experiences. Adapt programs into other languages or accessible formats. Establish annual targets for each product development strategy, so that the results can be compared to the desired or expected return.
Product Development. Attach all requested documentation and attach additional pages as necessary. For all requirements include efforts of all Sublicensees. If not applicable, please so indicate by N/A.
A. Provide the commercial name of any FDA-approved products, incorporating, using or that are Licensed Products/Licensed Methods that have first reached the market during the designated reporting Period. (This information is necessary for federal funding reporting requirements) Licensed Product (Name): Estimated Date of First Sale: FDA approval stage Contact Person Estimated Start Time Estimated End Time Estimated Budget Preclinical NDA Phase I Phase II Phase III Animal Studies Mfg./Production Facility Licensed Product (Name): Estimated Date of First Sale: Class Type: Completion Type: FDA Approval Stage Estimated Start Time Estimated End Time Estimated Budget PMA 501(k) IDE HDE Preclinical Phase I Phase II Phase III Mfg./Production Facility Licensed Product (Name): Estimated Date of First Sale: Contact Person Estimated Start Time Estimated End Time Estimated Budget Alpha Version Beta Version Commercial Version
Product Development. Except as otherwise expressly provided in Articles 2 and 3 hereof and in this Article 4, Wyeth shall have the sole authority, at its expense, for the Development of Licensed Products, including the initiation and conduct of clinical trials. Wyeth shall be responsible for the Development of and shall use its Commercially Reasonable Efforts to Develop Licensed Products throughout the Territory where it is Commercially Reasonable to do so (it being understood that Wyeth shall have the sole discretion to select those countries in which it will conduct clinical studies of Licensed Products and, when Commercially Reasonable to do so, to delay or discontinue the Development of any Licensed Product directed against a particular Licensed Target in favor of pursuing Development of another Licensed Product directed against such Licensed Target). When appropriate based on the data obtained during Development, Wyeth shall use its Commercially Reasonable Efforts to secure Regulatory Approval for Licensed Products in the Territory.
Product Development. Licensee shall use its reasonable efforts to test, develop the PRODUCT for commercial purposes throughout the world. On or before January 1 of each year during the term of this Agreement, commencing January 1,2003, Licensee shall submit to USC a report detailing its research, regulatory approval, marketing and product development objectives the coming year as well as the research, regulatory approval, marketing and development activities which Licensee undertook during the preceding year. The reports shall identify specific future milestones (regulatory approval and product development) and information demonstrating that the Licensee is providing sufficient financial and manpower resources to evidence its use of reasonable efforts. Within six (6) months after the signing of this Agreement and each two (2) years thereafter, a representative of the Office of Patent and Copyright Administration of USC, at Licensee's expense (including transportation, and, if appropriate, lodging and meals), shall visit the manufacturing and marketing facilities of Licensee and be presented with an in-depth updating of the manufacturing capability and marketing network of Licensee.
Product Development. SB shall have responsibility for, and control of, the development and commercialization of each Product arising from this Agreement, including process development, delivery system and formulation development, preclinical studies, clinical studies, sales and marketing.
Product Development. 3.1 Radius shall, at its own expense, carry out all necessary pre-clinical and clinical studies related to Compound and/or Product required by the relevant authorities throughout the Territory to achieve Product registration for the Product in those countries within the Territory for which Radius believes it should obtain registrations for Product in at least the United States, the United Kingdom, France, Germany, Italy and Spain. Radius shall use all its commercially reasonable efforts in developing Compound and/or Product in the Territory in accordance with its normal practices and procedures for pharmaceutical compounds having similar technical and commercial potential (taking into account issues of safety, efficacy, product profile, the competitiveness of the marketplace, the proprietary position of the product, the regulatory structure involved and profitability) and for which it has similar rights.
3.2 Radius shall use all its commercially reasonable efforts to obtain regulatory approvals for Product in the Territory as required for the manufacture, importation, marketing, promotion, pricing and sale of the Product(s) in those countries in the Territory where Radius seeks to market and sell Products. Attainment and maintenance of regulatory approvals for Product in the * Confidential Treatment Requested by the Registrant. Redacted Portion Filed Separately with the Commission. Territory shall be carried out by Radius. Radius shall bear all other expenses which it incurs in the attainment and maintenance of regulatory approvals and price registration activities in the Territory. Radius shall keep Eisai fully apprised of the status of regulatory approvals and price registrations in the Territory when it files for such approvals and when it receives such approvals.
3.3 The Parties intend and agree that the Development and commercialization of Products in the Territory shall be Radius’s responsibility and that Radius shall have full responsibility for, and control of, pre-clinical and clinical development and commercialization of Products in the Territory, including the authority to make all decisions, and undertake any actions necessary as a result of such decisions, regarding preclinical and clinical development plans and filing INDs and BLAs. Notwithstanding the foregoing, Radius shall provide Eisai the opportunity to provide input and suggestions into matters relating to the Development of Products, and Radius shall not unreasonably refuse to consider...
Product Development. The following obligations shall be in effect during the Initial Term of this Agreement only:
Product Development. All Royalty Bearing Products shall be developed, manufactured, marketed, and sold as "premium" products consistent with MFB's then existing image. Nonni's accepts full responsibility for and agrees to pay all costs it incurs associated with the development of all Royalty Bearing Products and all advertising and promotion, packaging design, graphics, and packaging materials for Royalty Bearing Products. MFB shall cooperate with Nonni's in development of Royalty Bearing Products, primarily through the suggestion of ideas, concepts, and recipes for products and packaging (MFB shall make its artwork, designs and logos available for Nonni's use); provided, however, that MFB shall have no obligation to develop Royalty Bearing Products or any other products.
Product Development. Except as otherwise provided in this Agreement, including but not limited to in the provisions of Exhibits F and G hereto, product development and manufacturing for the Products will be performed by Riverstone. In the event that Tellabs proposes new versions of line cards for the Products that Riverstone declines to develop, Tellabs will have the right [ * ]. Riverstone agrees that modifications requested by Tellabs may require software modifications, both in line card and in non- line card software. Riverstone will have the first right to perform the development of new Product line cards that are [ * ]. Tellabs will have the right to develop new line cards for installation into the Products, other than a [ * ], that are substantially based upon [ * ]. The parties will follow the procedures set forth in Exhibit G and will develop mutually agreed procedures that ensure that developments by Tellabs are adequately tested and integrated into the Products.